NCT01495910View on ClinicalTrials.gov

A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
21-hydroxylase Deficiency
Interventions
DRUG

Abiraterone acetate

Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.

Trial Locations (3)

Unknown

Chicago

Ann Arbor

Dallas

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT01495910 - A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency | Biotech Hunter | Biotech Hunter